Search for drugs:
Typing the drug name to query
VERAPAMIL HYDROCHLORIDE
DIR Classification
Classification:Moderate-DIR concern
Severity Score:3
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- PRECAUTIONS
- Drug Interactions
- HMG-CoA reductase inhibitors: The use of HMG-CoA reductase inhibitors that are CYP3A4 substrates in combination with verapamil has been associated with reports of myopathy/rhabdomyolysis.
- Co-administration of multiple doses of 10 mg of verapamil with 80 mg simvastatin resulted in exposure to simvastatin 2.5-fold that following simvastatin alone. Limit the dose of simvastatin in patients on verapamil to 10 mg daily. Limit the daily dose of lovastatin to 40 mg. Lower starting and maintenance doses of other CYP3A4 substrates (e.g., atorvastatin) may be required as verapamil may increase the plasma concentration of these drugs.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
Rhabdomyolysis
47
42865
Other ADRs
6307
14110972
Odds Ratio = 2.454
Drug Property Information
ATC Code(s):
- C08DA51 - verapamil hydrochloride
- C08DA - Phenylalkylamine derivatives
- C08D - SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
- C08 - CALCIUM CHANNEL BLOCKERS
- C - CARDIOVASCULAR SYSTEM
- C09BB10 - verapamil hydrochloride
- C09BB - ACE inhibitors and calcium channel blockers
- C09B - "ACE INHIBITORS, COMBINATIONS"
- C09 - AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- C - CARDIOVASCULAR SYSTEM
- C08DA01 - verapamil hydrochloride
- C08DA - Phenylalkylamine derivatives
- C08D - SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
- C08 - CALCIUM CHANNEL BLOCKERS
- C - CARDIOVASCULAR SYSTEM
Active Ingredient:verapamil hydrochloride
Active Ingredient UNII:V3888OEY5R
Drugbank ID:DB00661
PubChem Compound:2520
CAS Number:52-53-9
Dosage Form(s):tablet, extended release
Route(s) Of Administrator:oral
Daily Dose:
- 240.0 mg/day C08DA01
Chemical Structure: 
SMILE Code:
CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC
Reference
COHORT STUDY:
N/AOTHER REFERENCE(S):
N/ADisclaimer:
The content of this database of rhabdomyolysis is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
The views presented in this website do not necessarily reflect current or future opinion or policy of the US Food and Drug Administration. Any mention of commercial products is for clarification and not intended as endorsement.